Tempus AI Announces Six Rare Cancer Research Abstracts for 2026 CTOS Meeting
- Tempus AI will present six research abstracts at the Connective Tissue Oncology Society annual meeting in Seoul, Nov. 18-21, 2026.
- One study identifies gastrointestinal stromal tumor risk groups that predict prognosis better than clinical or molecular variables.
- Another study identifies a molecular signature in some SDH-deficient gastrointestinal stromal tumors, suggesting potential sensitivity to temozolomide.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261111240618) on November 11, 2026, and is solely responsible for the information contained therein.